IBX-001

IBX-001 is an investigational dermatologic drug candidate being developed by Aquavit Pharmaceuticals as a novel intradermal formulation for aesthetic and therapeutic skin applications. Publicly available data indicate that IBX-001 is part of Aquavit’s portfolio of microinjection-delivered agents for conditions such as skin rejuvenation and other cosmetic indications, but detailed information on its active ingredient, molecular target, and precise mechanism of action has not been disclosed. The product is administered via targeted intradermal delivery systems, suggesting a localized pharmacologic effect within the skin, yet its pharmacology, safety profile, and efficacy remain under evaluation in early- to mid-stage clinical development.